养阴剔络方干预老年代谢综合征炎症因子的临床研究
|
摘要
目的探讨养阴剔络方对老年代谢综合征患者炎症因子的影响,及对中医阴虚血瘀证疗效及安全性评价。
方法本实验共纳入69例符合代谢综合征西医诊断标准及阴虚血瘀证中医诊断标准的老年病人,其中男55人、女14人,年龄在60-89岁,随机分为观察组35人,对照组34人,观察组予养阴剔络方+西药基础治疗,对照组仅予西药基础治疗,观察时间三周,分别测定患者炎症因子(CRP、TNF、IL-6)治疗前后水平,并评估中医症状积分疗效,统计分析两组治疗结果。
结果观察组与对照组的年龄、性别、体重指数、肥胖、高血压、血脂异常、血糖异常分布、治疗前中医症状积分均无显著统计学差异(P值均>0.05),两组具有可比性。中医症状积分疗效结果提示,观察组治疗后积分低于对照组,疗效指数(51.12±13.07)高于对照组(39.23±13.67),观察组中显效2例、有效31例、无效2例,对照组中有效25例、无效9例,观察组疗效明显优于对照组。炎症因子结果提示,治疗后观察组CRP、TNF、IL-6水平降低,对照组水平未见明显改变,观察组疗效明显优于对照组。
结论1、养阴剔络方以养阴药与和瘀通络药相配伍,切合老年人代谢综合征肝肾阴虚、久病入络、瘀毒互结的基本病机,临床上能有效地改善阴虚血瘀证症状体征；2.养阴剔络方可降低老年代谢综合征患者CRP、TNF、IL-6水平,减轻体内炎症状态;3.养阴剔络方治疗老年代谢综合征是安全有效的；4.养阴剔络方能减轻老年代谢综合征阴虚血瘀证患者体内的炎症状态,对防治代谢综合征及其相关的心脑血管疾病的发生发展有重要的意义。
Objective To investigate the safety and effect of decreasing the inflammatory factors in elderly patients with metabolic syndrome typed in Yin deficiency blood stasis treating by the Nourishing-Yin-and-Dredging-Collateral formula.
Methods The study includes 69 elderly patients in accordance with western medicine diagnosis standard of MS and TCM diagnosis standard of yin deficiency blood stasis, among which male 55, female 14, age between 60 and 89, randomly being divided,35 into the observation group and 34 into the control group. The observation group is treated by the nourishing-Yin-and-Dredging-Collateral Formula and common western medicine. The control group was treated only by common western medicine.We carry out test of the inflammation factors (CRP、TNF、IL-6) before and after treatment, and make appraisal of the effect of the total points of TCM symptoms, finally conduct the statistic analysis.
Results There is no evident statistic difference(P>0.05) between the two groups about the distribution of age, gender, BMI, obesity, hypertension, blood lipid disorder, diabates, and the total points of the TCM symptoms. So they have comparability.The result of the total points of TCM symptoms told us, after treatment the total points of the observation group is lower than the control group, and the efficacy index is higher (51.12±13.07) than the control group (39.23±13.67).There is 2 cases of obvious effect,31 cases of common effect,2 cases of non-effect in the observation group. There is 25 cases of common effect,9 cases of non-effect in the control group. The effect of the observation group outperformed the control group. The result of the inflammation factors told us:the level of CRP、TNF、IL-6 is decreased after treatment in the observation group, and no significant change in the control group, the effect of observation group is better than control group.
Conclusion 1. The formula is combinated by the Nourishing-Yin herbs and Dredging-Collateral herbs.This compatibility fit the basic pathogenic principle of Asthenia of Hepatonephric Yin and Chronic Diseases Transforming to Collaterals for elderly patients with MS. It can improve the clinic TCM symptoms; 2.The formula decrease the inflammation factors (CRP、TNF、IL-6),and reduce inflammation in vivo; 3.It's safe and effective towards elderly MS by the Nourishing-Yin-and-Dredging-Collateral formula; 4. The formula can improve hemoendothelial malfunction in elderly MS patients typed in Yin deficiency blood stasis,it also has great significance of delaying senility of the vessels, and preventing from the onset and development of MS and its related cardio-cerebral vascular diseases.
方法本实验共纳入69例符合代谢综合征西医诊断标准及阴虚血瘀证中医诊断标准的老年病人,其中男55人、女14人,年龄在60-89岁,随机分为观察组35人,对照组34人,观察组予养阴剔络方+西药基础治疗,对照组仅予西药基础治疗,观察时间三周,分别测定患者炎症因子(CRP、TNF、IL-6)治疗前后水平,并评估中医症状积分疗效,统计分析两组治疗结果。
结果观察组与对照组的年龄、性别、体重指数、肥胖、高血压、血脂异常、血糖异常分布、治疗前中医症状积分均无显著统计学差异(P值均>0.05),两组具有可比性。中医症状积分疗效结果提示,观察组治疗后积分低于对照组,疗效指数(51.12±13.07)高于对照组(39.23±13.67),观察组中显效2例、有效31例、无效2例,对照组中有效25例、无效9例,观察组疗效明显优于对照组。炎症因子结果提示,治疗后观察组CRP、TNF、IL-6水平降低,对照组水平未见明显改变,观察组疗效明显优于对照组。
结论1、养阴剔络方以养阴药与和瘀通络药相配伍,切合老年人代谢综合征肝肾阴虚、久病入络、瘀毒互结的基本病机,临床上能有效地改善阴虚血瘀证症状体征；2.养阴剔络方可降低老年代谢综合征患者CRP、TNF、IL-6水平,减轻体内炎症状态;3.养阴剔络方治疗老年代谢综合征是安全有效的；4.养阴剔络方能减轻老年代谢综合征阴虚血瘀证患者体内的炎症状态,对防治代谢综合征及其相关的心脑血管疾病的发生发展有重要的意义。
Objective To investigate the safety and effect of decreasing the inflammatory factors in elderly patients with metabolic syndrome typed in Yin deficiency blood stasis treating by the Nourishing-Yin-and-Dredging-Collateral formula.
Methods The study includes 69 elderly patients in accordance with western medicine diagnosis standard of MS and TCM diagnosis standard of yin deficiency blood stasis, among which male 55, female 14, age between 60 and 89, randomly being divided,35 into the observation group and 34 into the control group. The observation group is treated by the nourishing-Yin-and-Dredging-Collateral Formula and common western medicine. The control group was treated only by common western medicine.We carry out test of the inflammation factors (CRP、TNF、IL-6) before and after treatment, and make appraisal of the effect of the total points of TCM symptoms, finally conduct the statistic analysis.
Results There is no evident statistic difference(P>0.05) between the two groups about the distribution of age, gender, BMI, obesity, hypertension, blood lipid disorder, diabates, and the total points of the TCM symptoms. So they have comparability.The result of the total points of TCM symptoms told us, after treatment the total points of the observation group is lower than the control group, and the efficacy index is higher (51.12±13.07) than the control group (39.23±13.67).There is 2 cases of obvious effect,31 cases of common effect,2 cases of non-effect in the observation group. There is 25 cases of common effect,9 cases of non-effect in the control group. The effect of the observation group outperformed the control group. The result of the inflammation factors told us:the level of CRP、TNF、IL-6 is decreased after treatment in the observation group, and no significant change in the control group, the effect of observation group is better than control group.
Conclusion 1. The formula is combinated by the Nourishing-Yin herbs and Dredging-Collateral herbs.This compatibility fit the basic pathogenic principle of Asthenia of Hepatonephric Yin and Chronic Diseases Transforming to Collaterals for elderly patients with MS. It can improve the clinic TCM symptoms; 2.The formula decrease the inflammation factors (CRP、TNF、IL-6),and reduce inflammation in vivo; 3.It's safe and effective towards elderly MS by the Nourishing-Yin-and-Dredging-Collateral formula; 4. The formula can improve hemoendothelial malfunction in elderly MS patients typed in Yin deficiency blood stasis,it also has great significance of delaying senility of the vessels, and preventing from the onset and development of MS and its related cardio-cerebral vascular diseases.
引文
1.孟明利,代谢综合征诊断指标的临床应用[J].实用医技杂志,2007,14(1)：119-120
2. Charles HL, Comel D, G regor JB. Tumor necrosisfacmr impairs insulin in action on peripheral glucose disposal and hepatic glucoseoutput[J]. Endocrinology.1992,130:43
3.何耀,封康,王洁.老年人群代谢综合征的患病率及其与心脑血管病的关系[J].中华老年心脑血管病杂志,2006,8(9)：597-600
4.脑卒中、冠心病发病危险因素进一步研究协作组.11省市队列人群代谢综合征的流行病学研究[J].中华预防医学杂志,2002,36(5)：298—300
5.孙向东,付丽琳.老年人群代谢综合征及其相关疾病患病情况分析[J].蚌埠医学院学报,2006,31(1)：55-56
6. WELLEN K E, HOTAMISL IGIL G S. Obesity-induced inflammatory changes in adipose tissue [J]. J Clin Invest,2003,112 (12):1785-1788
7. Ogihara T,Asano T, Katagiri H,et al1. Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B path-way and disrupting normal subcellular dist ribution of phosphate-dylinositol 3-kinase[J]. Diabetologia,2004,47(5):7941
8. Harold E.Hebovitz.代谢综合征临床意义和治疗干预[J].国外医学心血管疾病分册,2004,31(5)：
309-310
9. Williamson DF,VinicorF,Bowan BA. Primary prevention oftype-diabetes mellitus by lifestyle intervention: Implications for health policy[J]. Ann Intern Med,2004,140(11):951-957
10.郑刚,王佩显.贝特类药物调节代谢综合征血脂异常的作用[J].世界临床药物,2005,26(1)：30-33
11. Lkka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndromeand total cardiovascular disease mortality in middle-aged men[J]. JA-MA,2002,288(21):2790
12.徐成斌.代谢综合征(4)[J].中国医刊,2005,40(5)：258-261
13.徐成斌.代谢综合征(Metabolic Syndrome)(5)[J].中国医刊,2005,40(6)：322-324
14.高田伸树,代.谢综合征的药物治疗[J].日本医学介绍,2005,26(5)：221-223
15.王师菡,王阶,李霁,等.代谢综合征的中医辨证客观化研究[J].新中医,2007,39(11)：14-16
16.叶子,钟达锦.代谢综合征患者瘦素脂联素TNFa与中医辨证分型及兼症的关系[J].中医药学刊,2006,24(12)：2254—2256
17.王琦,李英帅.中医对代谢综合征的认识及辨治探讨(下)[J].浙江中医杂志,2006,41(11)：623—625
18.中华中医药学会.糖尿病中医防治指南[S]第1版.北京：中国医药科技出版社,2007.76—79
19.高志杨.益气养阴化瘀法治疗糖尿病伴高脂血症40例[J].浙江中西医结合杂志,2008,18(8)：482-483
20. 刘荣东,黄如萍,张玉辉.加味半夏白术天麻汤对痰湿壅盛型代谢综合征的影响[J].中华中医药 学刊,2008,26(10)：2242-2245
21.张苏明,梅爱农.代谢综合征、胰岛素抵抗与脑血管疾病[J].中华神经科杂志,2004,37(5)：468-470.
22. R idker PM, Hennekens CH, Buring JE, et al. C-reactive proteinand other markers of inflammation in the predictionof cardiovascular disease in women[J]. N Engl J M ed,2000,342::836-843.
23.邹大进,李慧.肥胖、炎症与胰岛素抵抗[J].国外医学内分泌学分册,2004,24(4)：S2-3
24. WeyerC, Yudkin JS, StehouwerCD, et al. Humoralmarketsofin—flammation and endotheliM dysfunction in relation to adipo sity and in viVO insulin action in Pima Indians[J]. Atherosclerosis,2002,161:23
25. SESSO H D, BUR ING J E, RIFA IN, et al1.C-reactive protein and therisk of develop in hypertension [J]. JAMA,2003,290 (22):2945-2951
26. Fried SK,Bunkin DA,Greenberg AS. Omentaland subcutaneous adipose tissues of obesesubjects release interleukin-6:depot difference and regulation by glucocorticoid[J]. Clin EndocrinolMetab 1998,83:847-850
27. Yudkin JS, Stehouwer CD, Emeis JJ, etal. C-reactive protein in healthy subjects:associationswith obesity, insulin resistance, and endothelial dysfunction:a potential rolefor cytokines originating from adipose tissue [J]. Arterioscler Thromb Vasc Biol,1999,19(4):972-978
28. Yudkin JS, Yajnik CS, Mohamed-Ali V,et al. High levels of circulating proinflam-matory cytokines and leptin in urban, bunot rural, Indians. A potential explanationfor increased risk of diabetes and coronaryheart disease [J]. Diabetes Care,1999,22(2):363-364
29. Bermudez EA, Rifai N, Buring J, et al. Interrelationships among circulating IL-6, C-reactive protein, and traditional cardiovascular risk factors in women [J]. Arte-rioscler Thromb Vasc Biol,2002,22(10): 1668-1673
30. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction amongapparently healthy men [J]. Circulation,2000,101(15):1767-1772
31. KANEMAKIT, ITADE H, KA1BORI M, et at. lnterleukin]beta and interleukin 6 but not tumor necrosis factor atpha'inhibitinsulin-stimulated glycogen synthesis in rat hepatoeytes[J]. Hepatology,1998,27(14): 1296-1303.
32. TSIGOS C, PAPAN1COLAOU D A, Kyrou I, et 81. Dose—dependent efects of recombinant human interleukin-6 on glucoseregulation[J]. Clin Endoerinol Metab,1997,82(21):4167—4170
33. Charles HL, Comel D, GregorJB. Tumor necrosisfacmr impairs insulin in action on peripheral glucose disposal and hepatic glucose output[J]. Endocrinology,1992,130:43
34. Churg A,Wang RD, Tai H, et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation viatumor necrosis factor-α release [J]. Respir CritMed,2003,167:1083-1089
35. Medina EA, Afsari RR, Ravid T, et al. Tumor necrosis factor-{alpha} decreases Akt protein levels in 3T3-L1 adipocytes via the caspase2dependent ubiquitination of Akt [J]. Endocrinology,2005,146:2726-2735
36. Shi H, Tzameli I, Bjorbaek C, et al. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling[J]. J Biol Chem,2004,279:34733-34740
37. de Alvaro C, Teruel T, Hernandez R, et al. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-deendent manner[J]. J Biol Chem, 2004,279:17070-17078
38. KimJA. Yeh DC, Ver M, et al. Phosphorylation of Ser24 in the pleckstrin homology domain of insulin receptor substrate-1 by Mouse Pelle-like kinase/interleukin-1 receptor-associatedkinase:cross-talk between inflammatory signaling and insulin signaling that may contribute to insulin resistance [J]. J BiolChem,2005, 280:23173-23183
39. Nordstrom EA, Ryden M, Backlund EC, et al. A human-specific role of cell death-inducing DFFA (DNA fragmentation factor-{alpha})-like effector A (CIDEA) in adipocyte lipolysis and obesity[J]. Diabetes,2005,54:1726-1734
40. DANDONAP, ALJADA A, MOHANTY P, et al. Insulin inhibits intranu clear nuclear factor kappa B and stimulates I-kappa B in mononuclear cells in obese subjects:evidence for an anti-inflammatory effect [J]. J Clin EndocrinolMetab,2001,86(12):3257-3265
41. ALJADA A, GHAN IM H, MOHANTY P, et al. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-lexp ression in mononuclear cells (MNC) and reduces plasma tissue factor(TF) and p lasminogen activator inhibitor-1 (PA I-1) concentrations [J]. J Clin Endocrino. Metab, 2002,87(3):1419-1422
42. TAKEBAYASH I K, ASO Y, INUKAI T. Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes [J]. Metabolism,2004,53 (6):693-699
43. STENTZ FB, UMP IERREZ GE, CUERVO R, et al. Proinflammatory cyto-kines, markers of cardiovascular risks, oxidative stress, and lipid peroxidetion in patients with hyperglycemic crises [J] Diabetes,2004,53(8):2079-2086
44. JESCHKEM G, KLE IN D, BOLDER U, et al. Insulin attenuates the systemic inflammatory response in endotoxemic rats [J]. Endocrinology,2004,145(9):4084-4093
45. HOTAM ISL IGIL G S. Inflammatory pathways and insulin action [J]. IntJ Obes RelatMetab Disord, 2003,27(13):S53-S55
46. SENN J J, KLOVER P J, NOWAKIA, et al. Suppressor of cytokine sig-Naling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes [J]. JB io Chem,2003,278(16): 13740-13746
47. EMANUELL IB, PERALD I P, F ILLOUX C, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alphain the adipose tissue of obesemice [J]. J B io Chem,2001,276 (51):47944-47949
48. RU IL, YUAN M, FRANTZ D, et al. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS 1 and IRS2 [J]. J B io Chem,2002,277 (44):42394-42398
49. Hotamisligil GS.Inflammatory pathways and insulin action.Int J Obes Relat Metab Disord 2003; 27 Suppl 3:S53-S55
50. Pickup JC, Crook MA. Is type Ⅱ diabetes mellitus a disease of innate immune system[J]. Diabetologia, 1998,41(10):1241.
51. JinW, Marchadier D. Rader DJ. Lipase and hDL metabolism [J]. Trends EndocrinolMetab,2002,13: 174-178
52.马洪亮,尹庆忠.2型糖尿病血清脂联素、炎性因子与胰岛素抵抗相关性研究[J].临床荟萃,2007,22(12)：870-871
53. Visser M, Bouter LM, Geraldine MM, et al. Elevated C-reactive protein levels in overweight and obese adults[J]. JAMA,1999,282(22):2121-2123
54. Trayhurn P, Beattie JH. Physiological role of adipose tissue:white adipose tissue as an endocrine and secretory organ[J]. Proc Nutr Soc,2001,60(3):329-339
55. Matsuzawa Y, Funahashi T, Nakamura T. Molecularmech-anism of metabolic syndrome X:contribution of adipocyto-kines, adipocyte-derived bioactive substances [J]. Ann NY Acad Sci,1999,892:146-154
56.陈晓蕾,周弘.代谢综合征发病机制研究进展[J].医学综述,2010,16(3)：431-433
57. Tyayhurn P, Beattie J H. Physiological role of adipose tissue:white adipose tissue as an endocrine and secretory organ [J]. Proceedings oft he Nutrition Society,2001,60(3):329-339
58.王卫民,曹萌.C反应蛋白与2型糖尿病胰岛素抵抗的关系探讨,中国民康医学,2008,20(13)：1421-1422
59. Hotamisligil GS, BudavariA, MurrayDL. etal. Reduced tyrosine kinase activitity of the insulin receptor in obesity-diabetes:Central role oftumor necrosis factor-a[J]. J C lin Invest,1995,94:1543
60. Hotamisligfl GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance[J]. J Clin Invest,1995,95(5):2409.
61. Hofmann C, Lorenz K,Braithwaite SS, et al. Altered gene expression for tumor necrosis factor'alpha and its receptors during drug and dietary modulation of insulin resistance [J]. Endocrinology,1994,134(1):264.
62.车志英,季聚良.益气养阴活血化痰法对2型糖尿病胰岛素抵抗患者白介秦6及肿瘤坏死因子-α的影响[J].时珍国医国药,2007,18(6)：1402-1403
63. Recasens M, Ricart W, Fernandez-Real JM. Obesity and inflammation[J]. Rev Med Univ Navarra, 2004,48(2):49-54
64. Chae CU, Lee RT,Rifai N, et al. Blood pressure and inflammation in apparently healthy men[J]. Hypertension,2001,38(3):399-403
65. Chrysohoou C, Pitsavos C, Panagiotakos DB, et al. Association between prehypertension status and inflammatory markers related to atherosclerotic disease:The ATTICA Study[J]. Am J Hyptertens,2004, 17(7):568-573
66. Bautista L E, Vera LM, Arenas IA, et al. Independent association between inflammatory markersC-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension[J]. J HumHypertens. 2005,19(2):149-157
67. Grundy SM, Abate N, Chandafia M. Diet composition and the metabolic syndrome:what is the optimal fat intake[J]. Am J Med,2002,1 (13):25S-29S
68.刘国良,纪红梅.代谢综合征与临床联系及处理特点[J].实用糖尿病杂志,2006,2(1)：3-5
69.黄晨征,覃春苑.国产盐酸吡格列酮对2型糖尿病患者CRP、IL-6的影响[J].实用诊断与治疗杂志,2008,22(5)：215-216
70.张骥,刘慧霞.生活干预加二甲双胍对老年代谢综合征患者CRP和IL—6水平的影响[J].中国医师杂志,2005,12(7)：1588-1590
71.姜良铎,张文生.从毒论治初探[J].北京中医药大学学报,1998；21(5)：2-3
72.陆付耳,李鸣真,叶望云.清热解毒治法研究的思路与方法[J].中国中西医结合杂志,2004；24(12)：1124-1129
73.雷燕.络病制胜论探微[J].北京中医药大学学报,1998； (2)：18-23.
74.袁长武,王建清.代谢综合证中医证型与白介素-6相关性研究[J].新疆中医药,2008,26(2)：24-27
75.张晓燕,宋鲁成.代谢综合征中医证型与Hs—CRP、TNF的相关性研究[J].山东中医药大学学报,2008,32(2)：123-125
76.倪永骋,陈江宁.高脂血症中医辨证分型与炎症因子的相关性研究[J].辽宁中医杂志,2007,34(1)：7-8
77.符德玉,祖亮华.3409例高血压病患者不同中医证型间心血管易损因子水平的变化[J].上海中医药大学学报,2009,23(3)：15-18
78.杨徐杭,汶医宁.炎症因子在冠心病中的意义及中药的干预作用[J].陕西中医学院学报,2007,30(6)：3-4
79.王霞,余江毅.中药对早期2型糖尿病炎症因子影响的研究[J]现代中西医结合杂志,2007,16(8)：1016-1017
80.杨泽平,蔡景英.丹参酮ⅡA磺酸钠治疗对2型糖尿病患者血管性假血友病因子和超敏C-反应蛋白的影响[J].中国医师杂志,2007,11(9)：1559-1560
81.张淑萍,李雅玲.中药野菊花对家兔模型SIL-2R、IL-6、TNF-α的影响[J].天津中医,2000,17(2)：34-36
82.包崑,毛炜.黄芪和雷公藤多甙对大鼠肾小球系膜细胞增殖及分泌IL-6影响的比较[J].广州中医药大学学报,2005,22(4)：292-295
83.龚敏,张卫萍.银杏叶制剂对冠心病患者血脂、血小板活化因子及C-反应蛋白的影响[J].陕西中医,2005,26(7)：636-637
84.尚改萍,文志斌.补阳还五汤对TNFa诱导血管内皮细胞释放vWF及表达组织因子的影响[J].湖南医科大学学报,2000,25(2)：129-131
85.王凌,李秋贵.参地降糖颗粒对胰岛素抵抗伴高血压模型大鼠胰岛素敏感性的影响[J].中医杂志,2010,51(1)：79-81
86.刘春玲,唐蜀华.芦黄颗粒对实验性动脉粥样硬化家兔C反应蛋白和白细胞介素6水平的影响[J].中国中西医结合急救杂志,2005,12(6)：366-368
87.周亚兵,罗若茵.酸味中药复方对实验性2型糖尿病大鼠胰岛素抵抗的影响[J].中国中西医结合杂志,2005,25(5)：441-444
88.雷燕.络病制胜论探微[J].北京中医药大学学报,1998；(2)：18-23
89.薛岚.中药虎杖的药理研究进展[J].中国中药杂志,2000,25(11)：651-653
90.肖立中,黄志.葛根素对急性心肌梗死患者梗死面积的影响及其机制探讨[J].中西医结合杂志,2004,24(9)：790-792
91.欧兴长,丁家欣.水蛭素的研究概况[J].中国药学杂志,1991；26(7)：396～399
92.龚峻梅,曲宏达.地龙及其提取物的药理作用介绍[J].暨南大学学报(医学版),2000,21(4)：133-135.
93.尹友生,李小励.地龙类药物对大鼠阳离子化牛血清白蛋白肾炎模型的影响[J].中国现代医学杂志,2005,15(13)：1974-1983
94. Xing J, WangSF. A ntiinflammatory effect of TCM and cytokines [J]. Ch in Tradit Herb Drugs(中草药),2001,32(5)：471-473
95.吴海云,王士雯.川芎嗪在急性冠状动脉综合征中抗炎作用的研究[J].中国中西医结合急救杂志,2004,11(4)：196-198
96.吴染荣,李友元,肖洒.黄精多糖调脂作用的实验研究[J].中国新药杂志,2003,12(3)：108-110
97.邢兰英,秦候喜,王金霞.黄精抗衰老作用的临床研究[J].吉林中医药,2005,25(8)：50-53
98.王浴生.中药药理与应用[M],人民卫生出版社,1998：41
99.李丽春,吴晓东,田维熙.何首乌提取物对脂肪酸合酶的抑制作用[J].中国生物化学与分子生物学报,2003,19(3)：297-30
100.杨新波,黄正明.枸杞多糖对正常小白鼠及四氧嘧啶致高血糖小鼠血糖的影响[J].人民军医药学专刊,1998,14(1)：11-13
101. SottM, Grund Y. Obesity metabolic sydrome, and cardiovascular discasa.[J]. Clin EndocrinolMetab, 2004,89(6):2595-2600
102.陈晓蕾.代谢综合征发病机制研究进展[J].医学综述,2010,16(3)：431-433
103. Hotamisligil GS. Inflammatory pathways and insulin action.Int [J]. Obes Relat Metab Disord 2003; 27 (3):S53-S55
104. Hellenius ML,Rauramaa R. The metabolic syndrome threatens public health Increased physical activity the best cure [J]. Lakar-tidningen,2007,104(51/52):3857-3861
2. Charles HL, Comel D, G regor JB. Tumor necrosisfacmr impairs insulin in action on peripheral glucose disposal and hepatic glucoseoutput[J]. Endocrinology.1992,130:43
3.何耀,封康,王洁.老年人群代谢综合征的患病率及其与心脑血管病的关系[J].中华老年心脑血管病杂志,2006,8(9)：597-600
4.脑卒中、冠心病发病危险因素进一步研究协作组.11省市队列人群代谢综合征的流行病学研究[J].中华预防医学杂志,2002,36(5)：298—300
5.孙向东,付丽琳.老年人群代谢综合征及其相关疾病患病情况分析[J].蚌埠医学院学报,2006,31(1)：55-56
6. WELLEN K E, HOTAMISL IGIL G S. Obesity-induced inflammatory changes in adipose tissue [J]. J Clin Invest,2003,112 (12):1785-1788
7. Ogihara T,Asano T, Katagiri H,et al1. Oxidative stress induces insulin resistance by activating the nuclear factor-kappa B path-way and disrupting normal subcellular dist ribution of phosphate-dylinositol 3-kinase[J]. Diabetologia,2004,47(5):7941
8. Harold E.Hebovitz.代谢综合征临床意义和治疗干预[J].国外医学心血管疾病分册,2004,31(5)：
309-310
9. Williamson DF,VinicorF,Bowan BA. Primary prevention oftype-diabetes mellitus by lifestyle intervention: Implications for health policy[J]. Ann Intern Med,2004,140(11):951-957
10.郑刚,王佩显.贝特类药物调节代谢综合征血脂异常的作用[J].世界临床药物,2005,26(1)：30-33
11. Lkka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndromeand total cardiovascular disease mortality in middle-aged men[J]. JA-MA,2002,288(21):2790
12.徐成斌.代谢综合征(4)[J].中国医刊,2005,40(5)：258-261
13.徐成斌.代谢综合征(Metabolic Syndrome)(5)[J].中国医刊,2005,40(6)：322-324
14.高田伸树,代.谢综合征的药物治疗[J].日本医学介绍,2005,26(5)：221-223
15.王师菡,王阶,李霁,等.代谢综合征的中医辨证客观化研究[J].新中医,2007,39(11)：14-16
16.叶子,钟达锦.代谢综合征患者瘦素脂联素TNFa与中医辨证分型及兼症的关系[J].中医药学刊,2006,24(12)：2254—2256
17.王琦,李英帅.中医对代谢综合征的认识及辨治探讨(下)[J].浙江中医杂志,2006,41(11)：623—625
18.中华中医药学会.糖尿病中医防治指南[S]第1版.北京：中国医药科技出版社,2007.76—79
19.高志杨.益气养阴化瘀法治疗糖尿病伴高脂血症40例[J].浙江中西医结合杂志,2008,18(8)：482-483
20. 刘荣东,黄如萍,张玉辉.加味半夏白术天麻汤对痰湿壅盛型代谢综合征的影响[J].中华中医药 学刊,2008,26(10)：2242-2245
21.张苏明,梅爱农.代谢综合征、胰岛素抵抗与脑血管疾病[J].中华神经科杂志,2004,37(5)：468-470.
22. R idker PM, Hennekens CH, Buring JE, et al. C-reactive proteinand other markers of inflammation in the predictionof cardiovascular disease in women[J]. N Engl J M ed,2000,342::836-843.
23.邹大进,李慧.肥胖、炎症与胰岛素抵抗[J].国外医学内分泌学分册,2004,24(4)：S2-3
24. WeyerC, Yudkin JS, StehouwerCD, et al. Humoralmarketsofin—flammation and endotheliM dysfunction in relation to adipo sity and in viVO insulin action in Pima Indians[J]. Atherosclerosis,2002,161:23
25. SESSO H D, BUR ING J E, RIFA IN, et al1.C-reactive protein and therisk of develop in hypertension [J]. JAMA,2003,290 (22):2945-2951
26. Fried SK,Bunkin DA,Greenberg AS. Omentaland subcutaneous adipose tissues of obesesubjects release interleukin-6:depot difference and regulation by glucocorticoid[J]. Clin EndocrinolMetab 1998,83:847-850
27. Yudkin JS, Stehouwer CD, Emeis JJ, etal. C-reactive protein in healthy subjects:associationswith obesity, insulin resistance, and endothelial dysfunction:a potential rolefor cytokines originating from adipose tissue [J]. Arterioscler Thromb Vasc Biol,1999,19(4):972-978
28. Yudkin JS, Yajnik CS, Mohamed-Ali V,et al. High levels of circulating proinflam-matory cytokines and leptin in urban, bunot rural, Indians. A potential explanationfor increased risk of diabetes and coronaryheart disease [J]. Diabetes Care,1999,22(2):363-364
29. Bermudez EA, Rifai N, Buring J, et al. Interrelationships among circulating IL-6, C-reactive protein, and traditional cardiovascular risk factors in women [J]. Arte-rioscler Thromb Vasc Biol,2002,22(10): 1668-1673
30. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction amongapparently healthy men [J]. Circulation,2000,101(15):1767-1772
31. KANEMAKIT, ITADE H, KA1BORI M, et at. lnterleukin]beta and interleukin 6 but not tumor necrosis factor atpha'inhibitinsulin-stimulated glycogen synthesis in rat hepatoeytes[J]. Hepatology,1998,27(14): 1296-1303.
32. TSIGOS C, PAPAN1COLAOU D A, Kyrou I, et 81. Dose—dependent efects of recombinant human interleukin-6 on glucoseregulation[J]. Clin Endoerinol Metab,1997,82(21):4167—4170
33. Charles HL, Comel D, GregorJB. Tumor necrosisfacmr impairs insulin in action on peripheral glucose disposal and hepatic glucose output[J]. Endocrinology,1992,130:43
34. Churg A,Wang RD, Tai H, et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation viatumor necrosis factor-α release [J]. Respir CritMed,2003,167:1083-1089
35. Medina EA, Afsari RR, Ravid T, et al. Tumor necrosis factor-{alpha} decreases Akt protein levels in 3T3-L1 adipocytes via the caspase2dependent ubiquitination of Akt [J]. Endocrinology,2005,146:2726-2735
36. Shi H, Tzameli I, Bjorbaek C, et al. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling[J]. J Biol Chem,2004,279:34733-34740
37. de Alvaro C, Teruel T, Hernandez R, et al. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-deendent manner[J]. J Biol Chem, 2004,279:17070-17078
38. KimJA. Yeh DC, Ver M, et al. Phosphorylation of Ser24 in the pleckstrin homology domain of insulin receptor substrate-1 by Mouse Pelle-like kinase/interleukin-1 receptor-associatedkinase:cross-talk between inflammatory signaling and insulin signaling that may contribute to insulin resistance [J]. J BiolChem,2005, 280:23173-23183
39. Nordstrom EA, Ryden M, Backlund EC, et al. A human-specific role of cell death-inducing DFFA (DNA fragmentation factor-{alpha})-like effector A (CIDEA) in adipocyte lipolysis and obesity[J]. Diabetes,2005,54:1726-1734
40. DANDONAP, ALJADA A, MOHANTY P, et al. Insulin inhibits intranu clear nuclear factor kappa B and stimulates I-kappa B in mononuclear cells in obese subjects:evidence for an anti-inflammatory effect [J]. J Clin EndocrinolMetab,2001,86(12):3257-3265
41. ALJADA A, GHAN IM H, MOHANTY P, et al. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-lexp ression in mononuclear cells (MNC) and reduces plasma tissue factor(TF) and p lasminogen activator inhibitor-1 (PA I-1) concentrations [J]. J Clin Endocrino. Metab, 2002,87(3):1419-1422
42. TAKEBAYASH I K, ASO Y, INUKAI T. Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes [J]. Metabolism,2004,53 (6):693-699
43. STENTZ FB, UMP IERREZ GE, CUERVO R, et al. Proinflammatory cyto-kines, markers of cardiovascular risks, oxidative stress, and lipid peroxidetion in patients with hyperglycemic crises [J] Diabetes,2004,53(8):2079-2086
44. JESCHKEM G, KLE IN D, BOLDER U, et al. Insulin attenuates the systemic inflammatory response in endotoxemic rats [J]. Endocrinology,2004,145(9):4084-4093
45. HOTAM ISL IGIL G S. Inflammatory pathways and insulin action [J]. IntJ Obes RelatMetab Disord, 2003,27(13):S53-S55
46. SENN J J, KLOVER P J, NOWAKIA, et al. Suppressor of cytokine sig-Naling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes [J]. JB io Chem,2003,278(16): 13740-13746
47. EMANUELL IB, PERALD I P, F ILLOUX C, et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alphain the adipose tissue of obesemice [J]. J B io Chem,2001,276 (51):47944-47949
48. RU IL, YUAN M, FRANTZ D, et al. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS 1 and IRS2 [J]. J B io Chem,2002,277 (44):42394-42398
49. Hotamisligil GS.Inflammatory pathways and insulin action.Int J Obes Relat Metab Disord 2003; 27 Suppl 3:S53-S55
50. Pickup JC, Crook MA. Is type Ⅱ diabetes mellitus a disease of innate immune system[J]. Diabetologia, 1998,41(10):1241.
51. JinW, Marchadier D. Rader DJ. Lipase and hDL metabolism [J]. Trends EndocrinolMetab,2002,13: 174-178
52.马洪亮,尹庆忠.2型糖尿病血清脂联素、炎性因子与胰岛素抵抗相关性研究[J].临床荟萃,2007,22(12)：870-871
53. Visser M, Bouter LM, Geraldine MM, et al. Elevated C-reactive protein levels in overweight and obese adults[J]. JAMA,1999,282(22):2121-2123
54. Trayhurn P, Beattie JH. Physiological role of adipose tissue:white adipose tissue as an endocrine and secretory organ[J]. Proc Nutr Soc,2001,60(3):329-339
55. Matsuzawa Y, Funahashi T, Nakamura T. Molecularmech-anism of metabolic syndrome X:contribution of adipocyto-kines, adipocyte-derived bioactive substances [J]. Ann NY Acad Sci,1999,892:146-154
56.陈晓蕾,周弘.代谢综合征发病机制研究进展[J].医学综述,2010,16(3)：431-433
57. Tyayhurn P, Beattie J H. Physiological role of adipose tissue:white adipose tissue as an endocrine and secretory organ [J]. Proceedings oft he Nutrition Society,2001,60(3):329-339
58.王卫民,曹萌.C反应蛋白与2型糖尿病胰岛素抵抗的关系探讨,中国民康医学,2008,20(13)：1421-1422
59. Hotamisligil GS, BudavariA, MurrayDL. etal. Reduced tyrosine kinase activitity of the insulin receptor in obesity-diabetes:Central role oftumor necrosis factor-a[J]. J C lin Invest,1995,94:1543
60. Hotamisligfl GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance[J]. J Clin Invest,1995,95(5):2409.
61. Hofmann C, Lorenz K,Braithwaite SS, et al. Altered gene expression for tumor necrosis factor'alpha and its receptors during drug and dietary modulation of insulin resistance [J]. Endocrinology,1994,134(1):264.
62.车志英,季聚良.益气养阴活血化痰法对2型糖尿病胰岛素抵抗患者白介秦6及肿瘤坏死因子-α的影响[J].时珍国医国药,2007,18(6)：1402-1403
63. Recasens M, Ricart W, Fernandez-Real JM. Obesity and inflammation[J]. Rev Med Univ Navarra, 2004,48(2):49-54
64. Chae CU, Lee RT,Rifai N, et al. Blood pressure and inflammation in apparently healthy men[J]. Hypertension,2001,38(3):399-403
65. Chrysohoou C, Pitsavos C, Panagiotakos DB, et al. Association between prehypertension status and inflammatory markers related to atherosclerotic disease:The ATTICA Study[J]. Am J Hyptertens,2004, 17(7):568-573
66. Bautista L E, Vera LM, Arenas IA, et al. Independent association between inflammatory markersC-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension[J]. J HumHypertens. 2005,19(2):149-157
67. Grundy SM, Abate N, Chandafia M. Diet composition and the metabolic syndrome:what is the optimal fat intake[J]. Am J Med,2002,1 (13):25S-29S
68.刘国良,纪红梅.代谢综合征与临床联系及处理特点[J].实用糖尿病杂志,2006,2(1)：3-5
69.黄晨征,覃春苑.国产盐酸吡格列酮对2型糖尿病患者CRP、IL-6的影响[J].实用诊断与治疗杂志,2008,22(5)：215-216
70.张骥,刘慧霞.生活干预加二甲双胍对老年代谢综合征患者CRP和IL—6水平的影响[J].中国医师杂志,2005,12(7)：1588-1590
71.姜良铎,张文生.从毒论治初探[J].北京中医药大学学报,1998；21(5)：2-3
72.陆付耳,李鸣真,叶望云.清热解毒治法研究的思路与方法[J].中国中西医结合杂志,2004；24(12)：1124-1129
73.雷燕.络病制胜论探微[J].北京中医药大学学报,1998； (2)：18-23.
74.袁长武,王建清.代谢综合证中医证型与白介素-6相关性研究[J].新疆中医药,2008,26(2)：24-27
75.张晓燕,宋鲁成.代谢综合征中医证型与Hs—CRP、TNF的相关性研究[J].山东中医药大学学报,2008,32(2)：123-125
76.倪永骋,陈江宁.高脂血症中医辨证分型与炎症因子的相关性研究[J].辽宁中医杂志,2007,34(1)：7-8
77.符德玉,祖亮华.3409例高血压病患者不同中医证型间心血管易损因子水平的变化[J].上海中医药大学学报,2009,23(3)：15-18
78.杨徐杭,汶医宁.炎症因子在冠心病中的意义及中药的干预作用[J].陕西中医学院学报,2007,30(6)：3-4
79.王霞,余江毅.中药对早期2型糖尿病炎症因子影响的研究[J]现代中西医结合杂志,2007,16(8)：1016-1017
80.杨泽平,蔡景英.丹参酮ⅡA磺酸钠治疗对2型糖尿病患者血管性假血友病因子和超敏C-反应蛋白的影响[J].中国医师杂志,2007,11(9)：1559-1560
81.张淑萍,李雅玲.中药野菊花对家兔模型SIL-2R、IL-6、TNF-α的影响[J].天津中医,2000,17(2)：34-36
82.包崑,毛炜.黄芪和雷公藤多甙对大鼠肾小球系膜细胞增殖及分泌IL-6影响的比较[J].广州中医药大学学报,2005,22(4)：292-295
83.龚敏,张卫萍.银杏叶制剂对冠心病患者血脂、血小板活化因子及C-反应蛋白的影响[J].陕西中医,2005,26(7)：636-637
84.尚改萍,文志斌.补阳还五汤对TNFa诱导血管内皮细胞释放vWF及表达组织因子的影响[J].湖南医科大学学报,2000,25(2)：129-131
85.王凌,李秋贵.参地降糖颗粒对胰岛素抵抗伴高血压模型大鼠胰岛素敏感性的影响[J].中医杂志,2010,51(1)：79-81
86.刘春玲,唐蜀华.芦黄颗粒对实验性动脉粥样硬化家兔C反应蛋白和白细胞介素6水平的影响[J].中国中西医结合急救杂志,2005,12(6)：366-368
87.周亚兵,罗若茵.酸味中药复方对实验性2型糖尿病大鼠胰岛素抵抗的影响[J].中国中西医结合杂志,2005,25(5)：441-444
88.雷燕.络病制胜论探微[J].北京中医药大学学报,1998；(2)：18-23
89.薛岚.中药虎杖的药理研究进展[J].中国中药杂志,2000,25(11)：651-653
90.肖立中,黄志.葛根素对急性心肌梗死患者梗死面积的影响及其机制探讨[J].中西医结合杂志,2004,24(9)：790-792
91.欧兴长,丁家欣.水蛭素的研究概况[J].中国药学杂志,1991；26(7)：396～399
92.龚峻梅,曲宏达.地龙及其提取物的药理作用介绍[J].暨南大学学报(医学版),2000,21(4)：133-135.
93.尹友生,李小励.地龙类药物对大鼠阳离子化牛血清白蛋白肾炎模型的影响[J].中国现代医学杂志,2005,15(13)：1974-1983
94. Xing J, WangSF. A ntiinflammatory effect of TCM and cytokines [J]. Ch in Tradit Herb Drugs(中草药),2001,32(5)：471-473
95.吴海云,王士雯.川芎嗪在急性冠状动脉综合征中抗炎作用的研究[J].中国中西医结合急救杂志,2004,11(4)：196-198
96.吴染荣,李友元,肖洒.黄精多糖调脂作用的实验研究[J].中国新药杂志,2003,12(3)：108-110
97.邢兰英,秦候喜,王金霞.黄精抗衰老作用的临床研究[J].吉林中医药,2005,25(8)：50-53
98.王浴生.中药药理与应用[M],人民卫生出版社,1998：41
99.李丽春,吴晓东,田维熙.何首乌提取物对脂肪酸合酶的抑制作用[J].中国生物化学与分子生物学报,2003,19(3)：297-30
100.杨新波,黄正明.枸杞多糖对正常小白鼠及四氧嘧啶致高血糖小鼠血糖的影响[J].人民军医药学专刊,1998,14(1)：11-13
101. SottM, Grund Y. Obesity metabolic sydrome, and cardiovascular discasa.[J]. Clin EndocrinolMetab, 2004,89(6):2595-2600
102.陈晓蕾.代谢综合征发病机制研究进展[J].医学综述,2010,16(3)：431-433
103. Hotamisligil GS. Inflammatory pathways and insulin action.Int [J]. Obes Relat Metab Disord 2003; 27 (3):S53-S55
104. Hellenius ML,Rauramaa R. The metabolic syndrome threatens public health Increased physical activity the best cure [J]. Lakar-tidningen,2007,104(51/52):3857-3861
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |